GlucoTrack, Inc. (NASDAQ:GCTK)

GlucoTrack, Inc. GCTK

Healthcare - Medical - Instruments & Supplies - NASDAQ - IL

Watchlist

$ 0.1401

-12.3 %

$ 3.58 M

Market Cap

None

P/E

1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GCTK stock under the worst case scenario is HIDDEN Compared to the current market price of 0.14 USD, GlucoTrack, Inc. is HIDDEN

GCTK Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GCTK stock under the base case scenario is HIDDEN Compared to the current market price of 0.14 USD, GlucoTrack, Inc. is HIDDEN

GCTK Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GCTK stock under the best case scenario is HIDDEN Compared to the current market price of 0.14 USD, GlucoTrack, Inc. is HIDDEN

GCTK Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart GCTK

FINANCIALS

Annual
Quarterly

-12.5 M OPERATING CASH FLOW

-104 K INVESTING CASH FLOW

13.7 M FINANCING CASH FLOW

-25.2 M OPERATING INCOME

-3.5 M OPERATING CASH FLOW

0 INVESTING CASH FLOW

8.78 M FINANCING CASH FLOW

Balance Sheet GlucoTrack, Inc.

5.93 M ASSETS
18.9 M LIABILITIES

Current Assets	5.77 M
Cash & Short-Term Investments	5.62 M
Receivables	0
Other Current Assets	151 K
Non-Current Assets	164 K
Long-Term Investments	0
PP&E	154 K
Other Non-Current Assets	10 K

Current Liabilities	1.28 M
Accounts Payable	992 K
Short-Term Debt	26 K
Other Current Liabilities	257 K
Non-Current Liabilities	17.7 M
Long-Term Debt	33 K
Other Non-Current Liabilities	17.6 M

EFFICIENCY

Earnings Waterfall GlucoTrack, Inc.

Revenue	0
Cost Of Revenue	0
Gross Profit	0
Operating Expenses	0
Operating Income	0
Other Expenses	22.6 M
Net Income	-22.6 M

RATIOS

0.00% OPERATING MARGIN

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis GlucoTrack, Inc.

Net Income	-22.6 M
Depreciation & Amortization	36 K
Capital Expenditures	-104 K
Stock-Based Compensation	173 K
Change in Working Capital	67 K
Others	9.64 M
Free Cash Flow	-12.6 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets GlucoTrack, Inc.

GCTK has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

GCTK does not distribute dividends.

5. COMPETITION

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

-55.7 USD

NXGL

Overvalued 2152.68%

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free.

1.02 K USD

LUCY

Undervalued 57724.92%

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

171 USD

PDEX

Undervalued 173.79%

6. Ownership

Insider Ownership GlucoTrack, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

24 M USD 2

6-9 MONTHS

1.1 M USD 4

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
1 year ago Apr 22, 2024	Bought 230 K USD	SYCOFF DREW director, 10 percent owner:	+ 182539.6	1.26 USD
10 months ago Jul 01, 2024	Bought 208 K USD	Goode Paul Chief Executive Officer	+ 2100	99 USD
10 months ago Jul 01, 2024	Bought 683 K USD	SYCOFF DREW director, 10 percent owner:	+ 138000	4.95 USD
10 months ago Jul 01, 2024	Bought 208 K USD	Goode Paul Chief Executive Officer	+ 42000	4.95 USD
8 years ago Mar 08, 2017	Bought 1 M USD	Darivoff Philip Director	+ 222223	4.5 USD
8 years ago Mar 08, 2017	Bought 1.72 M USD	Darivoff Philip Director	+ 222223	7.75 USD
8 years ago Mar 08, 2017	Bought 4.5 K USD	Darivoff Philip Director	+ 1000	4.5 USD
8 years ago Nov 30, 2016	Bought 517 K USD	Darivoff Philip Director	+ 66667	7.75 USD
8 years ago Nov 30, 2016	Bought 300 K USD	Darivoff Philip Director	+ 66667	4.5 USD
8 years ago Nov 30, 2016	Bought 1.35 K USD	Darivoff Philip Director	+ 300	4.5 USD

7. News

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention. globenewswire.com - 2 weeks ago

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data globenewswire.com - 4 weeks ago

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company. globenewswire.com - 1 month ago

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference globenewswire.com - 1 month ago

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology globenewswire.com - 2 months ago

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 2 months ago

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events reported globenewswire.com - 2 months ago

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes globenewswire.com - 3 months ago

Glucotrack Announces ISO 13485:2016 Certification ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor globenewswire.com - 3 months ago

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes globenewswire.com - 3 months ago

Glucotrack to Present at TechBio Showcase™ 2025 Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes globenewswire.com - 3 months ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks globenewswire.com - 4 months ago

8. Profile Summary

GlucoTrack, Inc. GCTK

COUNTRY IL

INDUSTRY Medical - Instruments & Supplies

MARKET CAP $ 3.58 M

Dividend Yield 0.00%

Description GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

Contact 8 Ariel Sharon Street, Or Yehuda, 7760049 https://www.glucotrack.com

IPO Date April 25, 2013

Employees 11

Officers Mr. Vincent Wong Vice President of Operations Mr. Avner Gal MBA, MSc.EE Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Mr. Mark Tapsak Ph.D. Chief Scientific Officer Mr. Peter C. Wulff Chief Financial Officer Mr. David Malka BA Co-Founder Ms. Drinda Benjamin Vice President of Marketing Mr. Paul V. Goode Ph.D. Chief Executive Officer, President & Director

Price Chart GCTK

GlucoTrack, Inc. GCTK

Free

Unlimited Plan

Premium Plan